Drug intelligence / Profile preview

Surv.m-CRA-2-IC

Development stage: Preclinical
Lead developer: Surv BioPharma
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravenous

Overview

Surv.m-CRA-2-IC is a Type 2 conditionally replicating oncolytic adenovirus (mCRA) developed by Surv BioPharma. The agent is engineered to selectively replicate within and destroy tumor cells (oncolysis) while sparing healthy tissue. Additionally, it is 'armed' with a therapeutic gene designed to stimulate the host's immune system against the cancer. Currently in the IND-enabling stage, Surv.m-CRA-2-IC is being developed for the treatment of various invasive and metastatic solid tumors.

Beyond the preview

Go deeper on Surv.m-CRA-2-IC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surv.m-CRA-2-IC.

Explore the full profile